文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-DOTA-TATE PET/CT 对转移性脊索瘤生长抑素受体表达的分子成像:与18F-FDG 的比较

68Ga-DOTA-TATE PET/CT for Molecular Imaging of Somatostatin Receptor Expression in Metastasizing Chordoma: Comparison With 18F-FDG.
PubMed 文献 · Clin Nucl Med · 2017-01-01

本文报告一例53岁男性转移性脊索瘤患者,为再分期及评估靶向放射性核素治疗潜力,接受了18F-FDG 与68Ga-DOTA-TATE PET/CT 检查;两种显像均见脊索瘤转移灶示踪剂摄取增高。作者指出,除葡萄糖代谢增高外,本病例还凸显了68Ga-DOTA-TATE PET/CT 用于脊索瘤再分期及靶向放射性核素治疗选择的潜力。

要点

  • 53岁男性转移性脊索瘤患者接受18F-FDG 与68Ga-DOTA-TATE PET/CT 再分期。
  • 两种 PET 显像均见脊索瘤转移灶示踪剂摄取增高。
  • 作者认为68Ga-DOTA-TATE PET/CT 在脊索瘤再分期与靶向放射性核素治疗方面有潜力。

核心结论

  • 作者认为,本病例除显示脊索瘤葡萄糖代谢增高外,还凸显了68Ga-DOTA-TATE PET/CT 用于脊索瘤再分期以及该病变靶向放射性核素治疗的潜力。

研究设计与样本

  • 个案报告:1例53岁男性转移性脊索瘤患者,为疾病再分期及评估靶向放射性核素治疗潜力,接受18F-FDG 与68Ga-DOTA-TATE PET/CT 检查。

主要发现

  • 18F-FDG 与68Ga-DOTA-TATE PET 显像均显示脊索瘤转移灶示踪剂摄取增高。
  • 作者指出脊索瘤存在葡萄糖代谢增高,并强调68Ga-DOTA-TATE PET/CT 在再分期及靶向放射性核素治疗方面的潜力。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chordoma is a rare slow-growing neoplasm of neuroectodermal origin, which frequently recurs after removal and has the potential to metastasize. We present the case of a 53-year-old man with metastasizing chordoma who underwent F-FDG and Ga-DOTA-TATE PET/CT for restaging of disease and for evaluation of targeted radionuclide therapy potential. On both F-FDG and Ga-DOTA-TATE PET scans, increased tracer accumulation was observed in chordoma metastases. Besides the increased glucose metabolism in chordoma, this case highlights the potential of Ga-DOTA-TATE PET/CT for restaging of chordoma as well the option of targeted radionuclide therapy in this entity.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Derlin T, Sohns JM, Hueper K, et al. 68Ga-DOTA-TATE PET/CT for Molecular Imaging of Somatostatin Receptor Expression in Metastasizing Chordoma: Comparison With 18F-FDG. Clin Nucl Med. 2017. PMID: 28166150. doi:10.1097/RLU.0000000000001576

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。